APIM Therapeutics completes private placement and enters phase-2

Published: Tue May 18 2021

APIM Therapeutics today announces the completion of a private placement directed towards existing and certain new investors in the Company. The proceeds from the investment round will be used to conduct a Phase-2 study in sarcoma.

The study will be initiated and conducted by a top Key Opinion Leader in a prominent health care institution and sarcoma research clinical center in the United States. The clinical study, which will be supported by the Company, is scheduled to start in Q3 2021. First efficacy data are expected in the second half of 2022.

Read more at APIM Therapeutics